Lyra Therapeutics (LYRA) Preferred Stock Liabilities (2019 - 2020)
Lyra Therapeutics (LYRA) recorded quarterly Preferred Stock Liabilities of $160.2 million in Q1 2020, up 22.6% on a QoQ basis from $130.7 million in Q4 2019, and up 22.82% YoY from $130.4 million in Q2 2019.
Lyra Therapeutics (LYRA) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Preferred Stock Liabilities for 2 consecutive years, with $160.2 million the latest figure, recorded in Q1 2020.
- Preferred Stock Liabilities for Q1 2020 came in at $160.2 million, up 22.82% year-over-year; the trailing twelve-month figure through Mar 2020 was $160.2 million (up 22.82% YoY), and the FY2019 annual result was $130.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2020 stood at $160.2 million, up from $130.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $160.2 million in Q1 2020, with the low at $130.4 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 160.20 Mn |
| Dec 31, 2019 | 130.67 Mn |
| Sep 30, 2019 | 130.59 Mn |
| Jun 30, 2019 | 130.51 Mn |
| Mar 31, 2019 | 130.43 Mn |